Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic. Issue 1 (1st January 2020)

• Record Type: Journal Article
• Authors: Qian, Kewen; Hu, Shi
• Is Part Of: MAbs. Volume 12:Issue 1(2020)
• Publication Date: 2020-01-01
• Subjects: SARS-CoV-2 -- SARS-CoV -- Ig-like proteins -- neutralization -- diffuse alveolar damage; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2020.1782600
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: While the potential therapeutic utility of angiotensin-converting enzyme 2 (ACE2) is well established, the clinical development of ACE2 drugs has been limited, likely due in part to the short half-life of the protein. In contrast, Ig-like ACE2 fusion proteins have exhibited greatly extended plasma half-life in vivo, and they have been shown to have a potent neutralization effect against SARS-CoV-2. Clinical investigation of Ig-like ACE2 fusion proteins as COVID-19 interventions is thus warranted.